scholarly journals Clinical Effect of Auricular Point Sticking in Patients with Lung Cancer Receiving Chemotherapy

2021 ◽  
Vol 5 (6) ◽  
pp. 73-77
Author(s):  
Xiaorui Zhu

Objective: To discuss and analyze the clinical effect of auricular point sticking in lung cancer chemotherapy. Methods: Sixty-two patients with lung cancer treated with chemotherapy in Suqian Traditional Chinese Medicine Hospital of Jiangxi Province were selected for case evaluation and analysis. The time span of the research was from June 2020 to June 2021. The patients were divided into two groups: a study group (n = 31) and a control group (n = 31) based on their medical record numbers. All the patients were treated with conventional western medicine before and after chemotherapy to prevent adverse reactions; however, the patients in the study group were also treated with auricular point sticking in addition to the former. The relevant indexes of the two groups were compared. Results: The incidence of adverse reactions was significantly lower in the study group compared to the control group (P < 0.05); the rate of symptomatic relief of the patients in the study group was higher than that of the control group (P < 0.05); the stress response indexes toward chemotherapy of the study group were better than those of the control group (P < 0.05). Conclusion: Auricular point sticking for patients with lung cancer who are receiving chemotherapy can reduce the incidence of adverse reactions, alleviate clinical symptoms, such as chest distress, asthma, and poor appetite, significantly alleviate stress response caused by chemotherapy, as well as promote the treatment effect; thus, it is worthy of promotion.

2021 ◽  
Vol 5 (6) ◽  
pp. 38-42
Author(s):  
Limei Qin

Objective: The main purpose of this study is to explore the efficacy of lung qi-diffusing and tumor-clearing decoction in the treatment of advanced lung cancer. Methods: Eight patients with advanced lung cancer in Inner Mongolia Baicaotang Qin’s Zhong Meng Medical Hospital from February 2017 to October 2020 were randomly selected and divided into two groups, a control group and a study group, by the digital table method. The control group was treated with conventional chemotherapy, while the study group was treated with lung qi-diffusing and tumor-clearing decoction on this basis. The therapeutic effects of the two groups were observed. Results: The improvement in symptoms of the patients in the study group was higher than that of the reference group, and the incidence of adverse reactions was lower among patients in the study group compared to the reference group, P < 0.05. The serum immunological indexes, CD3+, CD4+, and CD4+/CD8+, of study group were higher than those of the reference group, and the quality-of-life score of the study group was higher than that of the reference group, P < 0.05. Conclusion: The clinical effect of lung qi-diffusing and tumor-clearing decoction in the treatment of patients with advanced lung cancer is significant. It effectively improves the immune indicators and reduces adverse reactions.


2021 ◽  
Vol 5 (5) ◽  
pp. 52-56
Author(s):  
Limei Qin

Objective: This study mainly explores the clinical effect of Shashen Maidong Decoction in the treatment of advanced lung cancer. Methods: Twelve patients with advanced lung cancer from Inner Mongolia Baicaotang Qin’s Zhong Meng Medical Hospital were randomly selected from February 2016 to February 2021. They were divided into two groups: the reference group and study group by the digital table method. The reference group was treated with conventional chemotherapy while the study group was treated with Shashen Maidong Decoction plus conventional chemotherapy. Results: The remission rate of the study group was higher than that of the reference group, and the incidence of adverse reactions was lower than that of the reference group, P < 0.05. The levels of CD3+, CD4+, and CD4+/CD8+ in the study group were higher than those in the reference group (P < 0.05). After treatment, the quality of life score of the study group was higher than that of the reference group (P < 0.05). Conclusion: Shashen Maidong Decoction can effectively reduce adverse reactions and improve the condition of patients in the treatment of advanced lung cancer.


2020 ◽  
Vol 185 ◽  
pp. 03011
Author(s):  
Wentao Zhang ◽  
Ping Zuo ◽  
Feng Wang ◽  
Zhihua Liu ◽  
Yinglin Cui

To study the clinical effect of Huayu Tongluo Decoction combined with edaravone injection in the treatment of patients with acute cerebral infarction.86 patients with acute cerebral infarction received from our hospital from October 2016 to May 2018 were randomly divided into study group (n=43) and control group (n=43). Routine treatment was performed in both groups. On the basis of this, the control group was treated with edaravone injection, and the research group was treated with Huayu Tongluo Decoction combined with edaravone injection. The effects of treatment, the degree of neurological deficit (NIHSS score), TCM syndrome scores and quality of life (QLI score) before and after treatment were compared. The total effective rate of the study group [95.35% (41/43)] was higher than that of the control group [79.07% (34/43)] (P<0.05). After treatment, the main symptoms, secondary diseases and tongue and pulse of the two groups were treated. The scores were lower than before treatment, and the study group was lower than the control group (P<0.05). After treatment, the NIHSS and QLI scores of the two groups were better than before treatment, and the NIHSS score of the study group was lower than that of the control group, and the QLI score was higher than the control. Group (P<0.05). The clinical effect of Huayu Tongluo Decoction combined with edaravone injection in the treatment of patients with acute cerebral infarction is significant, which can further improve the clinical symptoms, improve neurological function and improve the quality of life.


2021 ◽  
Vol 20 (9) ◽  
pp. 1983-1989
Author(s):  
Yanfei Lv ◽  
Feng Dong ◽  
Hao Hao ◽  
Li Kong ◽  
Li Kong

Purpose: To investigate the therapeutic effect of combination of acupuncture and Ban Xia Xie Xin Decoction (BXXXD) in patients with sepsis-induced gastrointestinal dysfunction.Methods: A total of 100 patients with sepsis and gastrointestinal dysfunction admitted to our hospitalfrom June 2019 to December 2020 were randomly assigned to a control group and a study group for a retrospective analysis. Both groups received acupuncture treatment, while BXXXD was given to the study group, in addition to acupuncture. Treatment effectiveness, incidence of adverse reactions, degree of recurrence at 1, 2 and 3 months after treatment, gastrointestinal dysfunction scores after 1week of treatment, quality of life index (QLI) scores, frequencies of flatulence and defecation within 48 h, number of bowel rumblings, as well as levels of gastrin and  cholecystokinin (CCK), were determined and compared between the two groups.Results: The group with BXXXD intervention demonstrated superior treatment effectiveness, QLI cores, frequencies of flatulence and defecation within 48 h, number of bowel rumblings, and level of gastrin than those who received only acupuncture treatment (p < 0.05). There was strong evidence of lower incidence of adverse reactions, recurrence at 1, 2, and 3 months after treatment; gastrointestinal dysfunction scores and CCK levels after 1 week of treatment was higher in the study group than in the control group (p < 0.05).Conclusion: The combination of acupuncture and BXXXD is superior to acupuncture alone in sepsis patients with gastrointestinal dysfunction. The combination therapy produces its effect by decreasing clinical symptoms, promoting recovery of the patients, and elevating their quality of life.


Author(s):  
Huawei LIN ◽  
Jing CHANG ◽  
Jun LI

Background: To investigate the effects of docetaxel combined with icotinib on tumor markers in serum and quality of life of patients with advanced non-small cell lung cancer (NSCLC). Methods: Overall, 121 patients with advanced NSCLC, admitted to the Third Affiliated Hospital of Shandong First Medical University, China from 2017- 2018 were selected as subjects. Among them, 58 patients treated with docetaxel combined with icotinib for chemotherapy were considered as study group, and 63 patients treated with paclitaxel combined with carboplatin as control group. The clinical efficacy, adverse reactions, and ECOG scores of the two groups were observed. CEA, CA125, and SCC (Tumor markers) levels of the two groups before and after treatment were detected by chemiluminescence immunoassay (CLIA). Results: The leukopenia, oral mucosa ulcer and mild numbness in the control group were significantly higher than those in the study group (P<0.05). After treatment, ECOG scores of both groups decreased (P<0.05), and the ECOG score of the study group was significantly higher than that of the control group (P<0.05). The serum CEA, CA125 and SCC levels of the study group and the control group after treatment decreased significantly compared with that before treatment (P<0.05). Conclusion: Application of docetaxel combined with icotinib for chemotherapy of patients with advanced NSCLC can effectively reduce the serum levels of CEA, SCC, and the CA125. Docetaxel combined with icotinib can significantly reduce adverse reactions and better improve the quality of life of patients compared with paclitaxel combined with carboplatin, which is worthy of clinical promotion.  


2022 ◽  
Vol 2022 ◽  
pp. 1-6
Author(s):  
Zexin An ◽  
Yong Yin ◽  
Lei Zhang ◽  
Bo Wang ◽  
Tao Cui ◽  
...  

Objective. This study is aimed at exploring the effect of ulinastatin combined with Xingnaojing injection on severe traumatic craniocerebral injury and its influence on oxidative stress response and inflammatory response in patients. Methods. A total of 100 patients with severe traumatic craniocerebral injury admitted to our hospital from January 2018 to January 2020 were selected and equally assigned into a study group (50 cases) and a control group (50 cases) according to a random sampling method. Patients in study group received treatment of ulinastatin combined with Xingnaojing injection, while those in control group were treated with ulinastatin only. The study compared the two groups on the oxidative stress response, inflammatory response, the therapeutic effect, and the incidence rate of adverse reactions. Results. It is observed that patients in study group obtained lower levels of free cortisol (FC) and norepinephrine (NE) in the serum and higher level of total thyroxine (TT4) after treatment compared with those in control group with significant difference ( P < 0.05 ); in the meantime, they were examined to have significantly fewer oxidative stress response products, lower serum inflammatory factor level, and serum indicator levels of craniocerebral injury as opposed to those in control group, suggesting significant differences ( P < 0.05 ); study group demonstrated higher treatment response rate and lower incidence rate of adverse reactions compared with control group with a significant difference ( P < 0.05 ). Conclusion. The study found that ulinastatin combined with Xingnaojing infection has a significant effect in the treatment of severe traumatic craniocerebral injury, which can reduce the degree of craniocerebral injury and the level of inflammatory factors in the serum of patients. It is worthy of being promoted and applied clinically.


2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Xiaozheng Wu ◽  
Wen Li ◽  
Zhenliang Luo ◽  
Yunzhi Chen

Objective. To systematically review the efficacy and safety of Ligustrazine in the treatment of idiopathic pulmonary fibrosis (IPF). Methods. The electronic literature databases (PubMed, EMbase, CNKI, WanFang database, and VIP) were retrieved through a computer to find out the randomized controlled trials (RCT) of Ligustrazine in the treatment of IPF according to the inclusion/exclusion criteria screening test. Cochrane’s bias risk table was also used to evaluate the quality of the study and to extract effective data. RevMan 5.3 was used for statistical analysis. Results. A total of 7 RCTs (a total of 366 patients, including 196 in experimental and 170 in control group). Compared with the control group, Ligustrazine could improve the clinical symptoms ([OR] = 2.20, 95% CI [1.40, 3.46], P = 0.0006 ), lung function (VC % [MD] = 3.92, 95% CI [0.68, 7.17], P = 0.02 ), (TLC% [MD] = 4.94, 95% CI [0.37, 9.52], P = 0.03 ), the pulmonary diffusion function (DLCO % [MD] = 9.12, 95% CI [5.70, 12.55], P < 0.00001 ), and arterial blood gas analysis (PaO2 [MD] = 7.11, 95% CI [1.96, 12.25], P = 0.007 ) (PaCO2 [MD] = −2.42, 95% CI [−4.36, −0.49], P = 0.01 ) of IPF patients, respectively. However, FEV1/FVC % ([MD] = 9.37, 95% CI [−1.23, 19.97], P = 0.08 ) and adverse reactions ([MD] = 0.35, 95% CI [0.02, 5.36], P = 0.45 ) were not significantly improved. Conclusion. Ligustrazine has certain clinical efficacy in the treatment of IPF, but the safety of applying it and the adverse reactions need to be further analyzed and determined. It can be considered as a new alternative and complementary medicine to be promoted and recommended for use in medical units in various countries in the world and it solved the difficult problem of conventional drug treatment of IPF; therefore, more research strength can be put in the treatment of the pathological mechanism of IPF for further exploration. The study was registered under registration number CRD42020193626.


2020 ◽  
Vol 19 (2) ◽  
pp. 441-446
Author(s):  
Na Zheng ◽  
Ning Wang ◽  
Ji-Min Jia

Purpose: To determine the clinical efficacy of aripiprazole-olanzapine combination treatment in elderly Alzheimer’s disease complicated with mental disorders. Methods: Ninety-two elderly patients with Alzheimer’s disease and mental disorders who were admitted to Binzhou People's Hospital, were enrolled in the study. They were randomized into control and study groups. Control group was treated with olanzapine, while the study group was treated with aripiprazole as an adjuvant therapy in addition to olanzapine. The clinical efficacy, scores on different scales (MMSE, ADAS-cog, CDR, ADL, NPI and CMAI), and incidence of adverse reactions were determined. Results: The overall degree of response was significantly higher in the study group than in the control group (p < 0.05). There were no significant differences in MMSE, ADAS-cog, CDR, ADL, NPI and CMAI scores between the two groups before treatment (p > 0.05). The MMSE score of the study group was significantly higher than that of the control group, and the scores in the other scales in the study group were significantly lower after treatment (p < 0.05). The study group had significantly lower incidence of adverse reactions than control group (p < 0.05). Conclusion: Aripiprazole-olanzapine combination has significant therapeutic benefit in the treatment of elderly Alzheimer’s disease patients complicated with mental disorders. It promotes recovery of neurological function, as well as produces a lower incidence of adverse reactions. Keywords: Aripiprazole, Olanzapine, Alzheimer’s disease, Mental disorders


2013 ◽  
Vol 2 ◽  
pp. 7
Author(s):  
Li Liu

<p><strong>Objective: </strong>To study the clinical effect on the treatment of cardiac arrhythmia, and further guide the clinical treatment. <strong>Method: </strong>From January 2011 to January 2013, 100 patients with arrhythmia were randomly divided into observation group and control group with 50 cases in each group. Observation group patients given oral Stable heart granule treatment, while control group was treated with oral propafenone treatment. The therapeutic effect and adverse reactions of the two groups were observed and compared. <strong>Results: </strong>The total effective rate of the observation group was higher than control group and incidence of adverse reactions was lower than control group, the difference was statistically significant, <em>p</em> &lt; 0.05. The use of stable heart particles in the treatment of arrhythmia produce significant effect. <strong>Conclusion: </strong>Clinical effect for Stable heart granule on arrhythmia was significant and should widely entrenched in clinical practice.</p>


2021 ◽  
Author(s):  
Jing Wu ◽  
Hao Jiang ◽  
Liting Chen ◽  
Bingqi Yu ◽  
Zhibing Wu

Abstract Objective:The purpose of this study is to retrospectively observe the clinical efficacy and adverse reactions of docetaxel hyperthermic intraperitoneal chemotherapy (HIPEC) combined with endostar in treatment of malignant ascites. Methods:56 cases of malignant ascites admitted to Zhejiang Hospital from July 2019 and October 2020 had received no less than second-line chemotherapy. The observation group (n = 29) was treated with endostar 60mg d1,4,7 Q3W intraperitoneal injection combined with docetaxel 60mg/m2 d4 HIPEC Q3W for 2 cycles. The control group (n = 27) was just treated with docetaxel 60mg/m2 d1 HIPEC Q3W for 2 cycles. The general clinical data and qualitative data of the treatment results were processed by SPSS26.0 using χ2 test, and quantitative data were processed by t test. When P < 0.05, statistical data can be considered statistically significant.Results:There were significant differences between the observation group and the control group in objective response rate (ORR) (65.5% vs 37.0%,P=0.033),in the improvement rate of KPS (48.3% vs 22.2%, P=0.042),also in the median control time (57dvs 45d,P=0.027). The incidence of III to IV adverse reactions was low, and no treatment-related death was observed. There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion:Endostar combined with docetaxel HIPEC has good clinical effect on malignant ascites and can improve patients’ quality of life, and the adverse reactions can be tolerated.


Sign in / Sign up

Export Citation Format

Share Document